Outcomes of CheckMate 205, a phase II trial, confirm the efficacy of the anti-programmed cell death protein 1 (PD-1) antibody nivolumab in patients with Hodgkin lymphoma (HL) with treatment failure after autologous haematopoietic stem cell transplantation (auto-HSCT), regardless of prior treatment with brentuximab vedotin. A total of 243 patients were divided into three groups based on brentuximab vedotin treatment status: no previous treatment; treatment before auto-HSCT; or treatment after auto-HSCT. An objective response rate of 69% was observed across the entire study cohort, with response rates ≥63% observed in each group and a median progression-free survival duration of 14.7 months. Grade 3–4 adverse events were rare and included increased serum lipase levels (in 5% of patients) and neutropenia (3%). These findings demonstrate that nivolumab is safe and effective in this historically difficult to treat population, regardless of previous treatments received.
References
Original Article
Armand, P. et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J. Clin. Oncol. https://doi.org/10.1200/JCO.2017.76.0793 (2018)
Rights and permissions
About this article
Cite this article
Nivolumab effective in treatment-resistant HL. Nat Rev Clin Oncol 15, 402 (2018). https://doi.org/10.1038/s41571-018-0022-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-018-0022-2